Momentum from TD Cowen conference presentation fueled continued surge amid broader biotech weakness.
Shares broke to new 52-week highs starting March 4 during the company's presentation at the TD Cowen 46th Annual Health Care Conference, with trading up over 11% that day on elevated volume. Gains extended into March 5, hitting intraday peaks near $28.98, and persisted through March 6 despite a "red" day for biotech indices, as traders built on perceived positive updates from the event. No new announcements emerged, but the multi-day advance aligned with strong relative performance, corroborated by investor chatter noting the outlier strength ahead of Phase 2 trial data expected in late 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.